Product
Recombinant COVID-19 Vaccine
5 clinical trials
2 indications
Indication
COVID-19Indication
COVID-19 PneumoniaClinical trial
A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2023-01-10
Clinical trial
A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Single-arm, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Vector) for Inhalation in People 21 to 65 Years Old (Previously Primed With Authorized Vaccines)Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2023-11-01